Becker's ASC Review

13 EXECUTIVE BRIEFING 2 EXECUTIVE BRIEFING In using Olympus' colonoscopy-assisting technologies, endoscopists can significantly increase the detection of polyps. One meta-analysis evaluating the effectiveness of the ENDOCUFF VISION device in screening and surveillance procedures across five studies and 3,294 patients found that endoscopists' ADR increased from 49.3% without the device to 55.8% with the ENDOCUFF VISION device. 5 Another RCT evaluating the effectiveness of TXI technology compared to white light showed that it led to an ADR increase from 41.0% to 54.6%. 6 "At St. Luke's, in cases where we don't use the ENDOCUFF VISION device, we're finding precancerous polyps 41.2% of the time," Dr. Martins said. "For those where we do use it, we're finding precancerous polyps 52.2% of the time. So, with the ENDOCUFF VISION device, there's a significantly better chance of finding precancerous polyps and removing them." There is a learning curve associated with successfully using the device, but this learning curve is not daunting, Dr. Martins said. "It's important to try it out and give it some time to really feel comfortable with it," he said. "The more our doctors use it, the more comfortable they feel, both with insertion and withdrawal of the scope. Now, many of us want to use it for every colonoscopy case." In leveraging Olympus' technology, Dr. Pannu noted similar improvements at his practice in a short amount of time. "I have used the ENDOCUFF VISION device and TXI technology in combination for approximately six months and have seen an increase in ADR for both male and females in my practice by about 15% to 18%," he said. He explained TXI technology is particularly helpful in the detection of flat lesions, which are typically hard to see in white light — the conventional visualization mode that TXI technology also supports. He has also noticed a significant improvement in margin detection and surface pattern recognition while using TXI technology in underwater EMR. Dr. Pannu acknowledges there is a learning curve in maximizing the use of TXI technology, as well. "One gets used to it quickly, within a few uses," he said, noting that working with a local Olympus representative, who can help program the touch panel on the CV- 1500 video system center or the endoscope buttons to easily switch between white light and enhanced visualization, is essential to getting comfortable with the technology. Olympus' data-enriching tech creates opportunities for quality improvement Because ADR is an important quality metric, increasing ADR through the use of the ENDOCUFF VISION device and TXI technology during colonoscopies can be an important quality improvement opportunity for hospitals and GI practices. "We have one-on-one meetings with all of our doctors, during which we review each doctor's quality data and talk about what a doctor feels is going well and what they think could go better," Dr. Martins said. One way the ENDOCUFF VISION device supports colonoscopy quality improvement initiatives is by standardizing the withdrawal of the colonoscope from the colon, which is the optimal moment for detecting and removing precancerous polyps. "We take at least six minutes on average during withdrawal," Dr. Martins said. "There's very good evidence that doctors who withdraw the scope quicker than that are not finding precancerous polyps as often." At Dr. Pannu's facility, using the ENDOCUFF VISION device and TXI technology — sometimes in combination with additional artificial intelligence technologies — also helps standardize the colonoscopy procedure, which is an important consideration given existing differences in physician skill levels. Effectively leveraging Olympus' advanced colonoscopy tools requires consistency and collaboration Healthcare organizations interested in adding the ENDOCUFF VISION device and TXI technology to their colonoscopy toolkits should first consider several best practices and recommendations. For one, they should view acquiring these advanced tools as an investment in technology that improves patient care, Dr. Pannu said. Once organizations have adopted these technologies, they should give physicians enough time to familiarize themselves with each tool's features one by one, before moving on to the next. Then, organizations should strive to operationalize the ENDOCUFF VISION device and TXI technology consistently for all colonoscopy patients and track the respective ADRs, which will give a realistic picture of the true ADR. Finally, collaborating closely with Olympus representatives to obtain the necessary education and training is essential to implementing these tools in a way that meets physicians' needs and comfort levels. "Olympus has been instrumental in providing training to staff and physicians, being available in person for weeks at a time; setting up rooms with the new technology outside of our regular working hours; fine-tuning each room; and even programming buttons for physicians based on their preference," Dr. Pannu said. Dr. Martins shared a similar, hands-on experience — Olympus representatives worked with his team onsite and coached them through the process of using the ENDOCUFF VISION device. While introducing new clinical tools requires financial investment, organization-wide commitment, and the patience to navigate learning curves and change, both physicians agreed the effort is well worth it. "Adopting new technology can change the quality of patient care significantly, if done step by step with good support," Dr. Pannu said. At Olympus, we are committed to Our Purpose of making people's lives healthier, safer, and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide best-in-class solutions and services for early detection, diagnosis, and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states. For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world. For more information, visit www.olympusamerica.com LCR53267V02 5 Patel HK, Chandrasekar VT, Srinivasan S, Patel SK, Dasari CS, Singh M, Le Cam E, Spadaccini M, Rex D, Sharma P. Second-generation distal attachment cuff improves adenoma detection rate: meta-analysis of randomized controlled trials. Gastrointest Endosc. 2021 Mar;93(3):544-553.e7. doi: 10.1016/j.gie.2020.09.045. Epub 2020 Oct 5. PMID: 33031786. 6 Young E, Rajagopalan A, Tee D, et al. Texture and color enhancement imaging improves colonic adenoma detection: A multicenter randomized controlled trial. Gastroenterology. 2024;166(2):338-340.e3.

• Cover